Close



Apr 8, 2024 07:22AM
Apr 8, 2024 07:00AM
Mar 28, 2024 07:00AM
Mar 26, 2024 04:06PM
Mar 26, 2024 04:05PM
Feb 27, 2024 04:11PM
Feb 27, 2024 04:08PM Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Feb 27, 2024 04:05PM
Jan 2, 2024 07:01AM
Jan 2, 2024 07:00AM
Dec 12, 2023 12:00PM
Dec 12, 2023 12:00PM
Dec 11, 2023 07:30AM
Dec 11, 2023 07:30AM Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
Dec 10, 2023 05:00PM
Nov 21, 2023 09:00AM
Nov 2, 2023 04:05PM
Nov 2, 2023 09:05AM
Nov 2, 2023 09:00AM
Nov 2, 2023 09:00AM
Oct 24, 2023 07:00AM Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
Oct 24, 2023 07:00AM
Oct 2, 2023 07:04AM
Oct 2, 2023 07:00AM
Jul 24, 2023 07:02AM
Jul 24, 2023 07:00AM
Jul 11, 2023 06:19AM
May 8, 2023 04:05PM Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
Mar 15, 2023 04:06PM
Mar 15, 2023 04:05PM
Feb 28, 2023 04:03PM
Dec 10, 2022 05:00PM
Dec 5, 2022 07:16AM
Dec 5, 2022 07:15AM
Nov 3, 2022 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
Nov 3, 2022 09:03AM
Nov 3, 2022 09:00AM
Aug 8, 2022 04:05PM
May 9, 2022 04:05PM
Mar 1, 2022 04:05PM
Feb 8, 2022 07:30AM
Dec 22, 2021 07:01AM Syndax Pharmaceuticals' (SNDX) SNDX-5613 Granted Orphan Drug Designation in Europe for Treatment of Acute Myeloid Leukemia
Dec 22, 2021 07:00AM
Dec 16, 2021 09:26AM
Dec 15, 2021 05:46PM
Dec 13, 2021 02:46PM
Dec 13, 2021 02:45PM
Dec 13, 2021 05:13AM
Dec 11, 2021 02:00PM Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
Dec 9, 2021 04:05PM

251,409 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All